Plaque Volume Predicts Risk of Major Adverse Cardiovascular Events
Post-hoc analysis of a 4,267-patient randomized trial found higher total and noncalcified plaque volumes on CCTA independently predict major adverse cardiovascular events (MACE).
Why it mattersCCTA-measured TPV predicts MACE, so clinicians and trialists should prioritize TPV-guided therapeutic escalation.